NCT06951932 (MCI-MCT) is a NA clinical trial of Mediterranean-type diet with MCT supplementation in Mild Cognitive Impairment (MCI), sponsored by Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria.

Who is sponsoring NCT06951932?

NCT06951932 is sponsored by Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria.

What drugs are being tested in NCT06951932?

Interventions in NCT06951932: Mediterranean-type diet with MCT supplementation, Mediterranean-type food regimen using extra virgin olive oil.

What condition does NCT06951932 study?

NCT06951932 studies Mild Cognitive Impairment (MCI).

Is NCT06951932 still recruiting?

NCT06951932 is currently recruiting now. Last updated 4 May 2025.

Last reviewed 2025-05-04 · How we verify

NCT06951932: MCI-MCT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of the Impact of Medium-chain Fatty Acids in the Evolution of Newly Diagnosed Mild Cognitive Impairment

Recruiting now NA Last updated 4 May 2025

What this trial tests

NA trial testing Mediterranean-type diet with MCT supplementation in Mild Cognitive Impairment (MCI) in 120 participants. Currently enrolling.

Timeline

3 July 2024

Primary endpoint
3 July 2025

3 November 2025

Quick facts

Lead sponsor	Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	120
Start date	3 July 2024
Primary completion	3 July 2025
Estimated completion	3 November 2025
Sites	1 location across Italy

Drugs / interventions tested

Mediterranean-type diet with MCT supplementation
Mediterranean-type food regimen using extra virgin olive oil

Conditions studied

Mild Cognitive Impairment (MCI) — all drugs for Mild Cognitive Impairment (MCI) →

Sponsor

Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria — full company profile →

Who can join

Adults 18 to 85, any sex, with Mild Cognitive Impairment (MCI). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Mild cognitive impairment (MCI) is considered the intermediate stage between the changes observed in physiological aging and dementia. Currently, there is no drug therapy, and available drugs offer only minimal benefit on symptoms, only partially slowing the course of the condition. Studies in the literature have investigated the role of omega-3 fatty acids in MCI, and when administered over a period of six months, they appear to improve clinical condition and mood. In addition, medium-chain triglycerides (MCTs) appear to exert an antioxidant function, enhance cognitive ability in patients with MCI or Alzheimer's, and promote deep sleep state.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Mild Cognitive Impairment (MCI)

Currently open trials in the same condition.

NCT07516119 — Predicting Pre-dementia · recruiting
NCT07526740 — Brain Stimulation and Cognitive Training for MCI · NA · recruiting
NCT07101380 — Feasibility Study of 'SuperBrain BOOM' for Mild Cognitive Impairment Patients · NA · recruiting
NCT07420426 — Instant Message-delivered Personalised Acceptance and Commitment Therapy (IMPACT) for Neuropsychiatric Symptoms in Perso · NA · recruiting
NCT07286448 — Personalized Digital Training for COGnitive FITness in Mild Cognitive Impairment · NA · recruiting

Other Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria trials

Trials by the same sponsor.

NCT07499141 — Use of Fluorescence in Gliomas · completed
NCT06296277 — Mechanical Ventilation in Surgical Patients · not yet recruiting
NCT07252076 — PRetreatment MRI for OCcult Liver Metastasis Assessment In Pancreatic Ductal adenocarcinoMa · recruiting
NCT06960044 — Procalcitonin Aided Antimicrobial Therapy vs Standard of Care · NA · not yet recruiting
NCT07150871 — Impact of Covid-19 on Syphilis · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06951932 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria
Last refreshed: 4 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06951932.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing